国际皮肤性病学杂志    2003 29 (3): 144-146   ISSN: 2096-5540  CN: 32-1880/R   他克莫司和匹美克莫司的局部应用 唐鸿珊1, 朱一元2 1. 安徽省立医院皮肤科, 合肥230001; 2. 安徽医科大学附属第一医院皮肤科 收稿日期 2002-09-26  修回日期 null  网络版发布日期 null 参考文献  [1] Bekersky I, Lilja H, Lawrence I. Tacrolimus pharmacology and nonclinical studies:from FK506 to protopic. Semin Cutan Med Surg,2001,20(4):226-232. [2] Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel,SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg, 2001, 20(4):233-241. [3] Boguniewicz M, Leung DY. Pathophysiologic mechanisms in atopic dermatitis. Semin Cutan Med Surg, 2001,20(4):217-225. [4] Bergman J, Rico MJ. Tacrolimus clinical studies for atopic dermatitis and other conditions. Semin Cutan Med Surg, 2001, 20 (4):250-259. [5] Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehiclecontrolled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol, 1998, 102(4 Pt 1):637-644. [6] Eichenfield LF, Lucky AW, Boguniewicz M,et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol, 2002, 46(4):495-504. [7] Reitamo S, Van Leent E J, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol, 2002, 109(3):539-546. [8] Ling MR. Topical tacrolimus and pimecrolimus:future directions. Semin Cutan Med Surg, 2001, 20(4):268-274. [9] Mrowietz U, Graeber M, Brautigam M, et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol, 1998, 139(6):992-996. [10] Zonneveld IM, Rubins A, Jablonska S, et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol, 1998, 134(9):1101-1102. [11] McElwee KJ, Rushton DH, Trachy R, et al. Topical FK506:a potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model. Br J Dermatol, 1997, 137(4):491-497. [12] Yamamoto S, Jiang H, Kato R. Stimulation of hair growth by topical application of FK506, a potent immunosuppressive agent. J Invest Dermatol, 1994,102(2):160-164. [13] Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease:a case series of 18 patients. Arch Dermatol, 2001, 137(9):1202-1206. 通讯作者: